The Genuair® inhaler: A novel, multidose dry powder inhaler

International Journal of Clinical Practice

Volumn 66, Issue 3, 2012, Pages 309-317

  Chrystyn, H ^a   Niederlaender, C ^b  

^a UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^b Almirall SA ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MOXIFLOXACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TIOTROPIUM BROMIDE;

AEROSOL; AIRFLOW; AUDITORY FEEDBACK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DISPERSION; HUMAN; IN VITRO STUDY; MECHANICAL STRESS; POWDER INHALER; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW; SINGLE DRUG DOSE; TEMPERATURE STRESS; VISUAL FEEDBACK;

ADMINISTRATION, INHALATION; AEROSOLS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; MUSCARINIC ANTAGONISTS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES;

EID: 84857262977     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02832.x     Document Type: Review

References (41)

1. IMS Health, IMS MIDAS. Retail Sales Audit 2000-2010, Danbury, CT: IMS Health, 2011.
2. Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. Br Med J 1976; 1: 76-7.
3. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982; 119: 101-4. (Pubitemid 12060363)
4. Hauck HR. Do medical CFCs threaten the environment? J Aerosol Med 1991; 4: 169-74.
5. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293-304.
6. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999; 186: 3-12. (Pubitemid 29397518)
7. Lavorini F, Magnan A, Dubus JC, et al., Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102: 593-604.
8. Molimard M, Raherison C, Lignot S, et al., Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16: 249-54. (Pubitemid 37169635)
9. Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50: 1304-12. (Pubitemid 46173313)
10. O'Connor BJ. The ideal inhaler: design and characteristics to improve outcomes. Respir Med 2004; 98 (Suppl A): S10-6. (Pubitemid 38578716)
11. Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. In:, Dalby RN, Byron RR, Peart PR, Suman JD, Young PM, Eds. River Grove, IL, USA: Davis Healthcare International Publishing, 2009: 105-16.
12. Feddah MR, Brown KF, Gipps EM, Davies NM. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000; 3: 318-24.
13. Smith K, Chan HK, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 1998; 11: 231-45. (Pubitemid 28563962)
14. Laube BL, Janssens HM, de Jongh FH, et al., What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-31.
15. Moeller M, Fritsche D, Rivera D, Libertus H. Improvement of asthma therapy by a novel budesonide multidose dry powder inhaler. Arzneimittelforschung 2003; 53: 562-7. (Pubitemid 37011506)
16. Otto-Knapp R, Conrad F, Hosch S, et al., Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma. Pulm Pharmacol Ther 2008; 21: 47-53.
17. Welte T, Metzenauer P, Hartmann U. Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD-a double-blind, randomised, controlled trial. Pulm Pharmacol Ther 2008; 21: 4-13.
18. Mueller S, Wedel M, Fyrnys B. Performance characteristics of a multidose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems. Poster presented at the European Respiratory Society Annual Congress, Glasgow, Scotland, 4-8 September 2004.
19. Draft-Guidance for Industry: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products: chemistry, manufacturing, and controls documentation, edited by the FDA in October 1998. (accessed April 2011).
20. Greguletz R, Fyrnys B, Goede J, de Boer AH, Frijlink HW. A novel multidose dry powder inhaler demonstrates consistent aerodynamic features. Poster J91 presented at the American Thoracic Society International Conference, San Diego, CA, USA, 15-20 May 2009.
21. Block K, Folger S, Fyrnys B, Kurtz S. Delivered dose and fine particle dose of aclidinium bromide 200 ug via the Genuair® inhaler are independent of flow rate within the working range of the device. Poster presented at the European Respiratory Society Annual Congress, Barcelona, Spain, 18-22 September 2010.
22. Block K, Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler. Poster B58 presented at the American Thoracic Society International Conference, New Orleans, LA, USA, 14-19 May 2010.
23. Magnussen H, Watz H, Zimmermann I, et al., Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD. Respir Med 2009; 103: 1832-7.
24. Greguletz R, Fyrnys B, Goede J, Herder M. The Genuair® inhaler: a reliable device technology in inhalation therapy. Poster B57 presented at the American Thoracic Society International Conference, New Orleans, LA, USA, 14-19 May 2010.
25. Greguletz R, Arlt M, Anke S, et al., A novel multidose dry powder inhaler for the delivery of various types of inhalation powder. Poster presented at the American Thoracic Society International Conference, San Diego, CA, USA, 15-20 May 2009.
26. Block K, Folger S, Fyrnys B. Stability of aclidinium bromide inhalation powder (200 μg per dose) delivered from the Genuair® inhaler. Poster B56 presented at the American Thoracic Society International Conference, New Orleans, LA, USA, 14-19 May 2010.
27. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration 2009; 78: 322-8.
28. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001; 14: 281-7. (Pubitemid 32802030)
29. Hass C, Engdahl K, Albert W, Setyawan J, Mateo N. Patient preferences and perceived ease of use in inhaler features: Genuair vs. other inhalers. Poster presented at the American College of Chest Physicians Annual Congress, Vancouver, Canada, from 30 October to 4 November 2010.
30. Schmid K, Pascual S, Garcia Gil E, Ortiz S, Jansat JM. Pharmacokinetics and safety of acldinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010; 32: 1798-812.
31. Ortiz S, Flach S, Caracta C, Garcia Gil E, Jansat JM. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 2011; Epub ahead of print. 31st May 2011.
32. Jansat JM, Lamarca R, de MG, et al., Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009; 49: 1239-46.
33. Lasseter KC, Aubets J, Chuecos F, Gil EG. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 2011; 51: 923-32.
34. de Miquel G, Schrodter A, Miletzki B, et al., Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses. Am J Resp Crit Care Med 2008; 177: A655.
35. de la Motte S, Beier J, Schmid K, et al., Pharmacokinetics of aclidinium bromide 200 μg and 400 μg in young and elderly patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2010; 181: 4446 [abstract].
36. Vestbo J, Vogelmeier C, Creemers J, et al., Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010; 7: 331-6.
37. Chanez P, Burge PS, Dahl R, et al., Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010; 23: 15-21.
38. Fuhr R, Magnussen H, Sarem K, et al., Efficacy of aclidinium bromide 400 μg BID compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest 2011; Epub ahead of print. 8th September 2011.
39. Maltais F, Celli B, Casaburi R, et al., Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105: 580-7.
40. Kerwin EM, D'Urzo A, Gelb AF, et al., Twice-daily aclidinium bromide in COPD patients: efficacy and safety results from ACCORD COPD I. Eur Respir J 2010; 36: 219s.
41. Jones PW, Rennard SI, Agusti A, et al., Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 1-10.